Our Science
Pipeline
Name of The Drug
Research Type/Indication
Development Phase
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
Dorzagliatin
T2D - Drug Naïve
Launched (China)
T2D - Metformin Tolerated
Launched (China)
RWE study for Diabetes Remission
Launched (China)
Diabetes Prevention
Pre-clinical
Neurodegeneration
Pre-clinical
Dorzagliatin and Metformin FDC
T2D
Phase I
Dorzagliatin + Empagliflozin
DKD
Phase II
Dorzagliatin + Sitagliptin
T2D
Phase II
Dorzagliatin add on to GLP1RA
T2D and Obesity
Phase I
Dorzagliatin add on to Insulin
T1D
Pre-clinical
2nd Generation GKA
Metabolic Disease
Phase I
mGLUR5 NAM
PD-LID
Pre-clinical
Drug Addiction
Pre-clinical
GK NAM
Metabolic Disease
Pre-clinical
Dorzagliatin
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T2D - Drug Naïve
Launched (China)
T2D - Metformin Tolerated
Launched (China)
RWE study for Diabetes Remission
Launched (China)
Diabetes Prevention
Pre-clinical
Neurodegeneration
Pre-clinical
Dorzagliatin and Metformin FDC
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T2D
Phase I
Dorzagliatin + Empagliflozin
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
DKD
Phase II
Dorzagliatin + Sitagliptin
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T2D
Phase II
Dorzagliatin add on to GLP1RA
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T2D and Obesity
Phase I
Dorzagliatin add on to Insulin
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T1D
Pre-clinical
2nd Generation GKA
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
Metabolic Disease
Phase I
mGLUR5 NAM
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
PD-LID
Pre-clinical
Drug Addiction
Pre-clinical
GK NAM
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
Metabolic Disease
Pre-clinical
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
沪ICP备14036654号-1
沪公网安备 31011502013809号
Search
